Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882557 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
A Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT00882557 is a Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 16 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00882557, a Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
Conditions Studied
Interventions
- DRUG daptomycin
Study Locations (2)
California
- West Coast Clinical Trials - Cypress
Minnesota
- DaVita Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-04-29 |
| Est. Completion | 2009-07-17 |
| Phase | Phase 1 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882557
The ClinicalTrials.gov registry entry for NCT00882557 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The listed sponsor is Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which daptomycin is the first listed.
NCT00882557 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00882557 about?
NCT00882557 is a clinical study titled "Study to Evaluate Daptomycin Given During Dialysis and After Dialysis". The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
What is the current status of trial NCT00882557?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-04-29. Estimated completion is 2009-07-17.
What conditions does trial NCT00882557 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis.
What interventions are being tested in trial NCT00882557?
The interventions under investigation include: daptomycin (DRUG).
Who is sponsoring clinical trial NCT00882557?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00882557 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
Explore more on PlainTrial
End Stage Renal Disease
All registered trials for this condition
Renal Failure Chronic Requiring Hemodialysis
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.